Summary
Questions are swirling about whether committee members who voted this month at the Food and Drug Administration had financial ties that biased them to keep three popular arthritis medicines on the market. But a physician who served on the committee says the controversy is overblown.
"I'm surprised that the outcome of the vote is being perceived as a result of panel members having affiliations with industry and conflicts of interest, when the vote was perfectly compatible with the evidence," said Dr. Susan Manzi, a University of Pittsburgh authority on lupus who serves on one of the two FDA committees that voted on the drugs. "I think the process worked."See the full content of this document
Extract
Adviser Rebuts Ethics Worry
A researcher at the Center for Scie...
See the full content of this document
Sponsored links
